Loading clinical trials...

Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome | Clinical Trials | Clareo Health

UNKNOWNNA

Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome

Evaluation of Repeating Low-intensity Shockwave Therapy (LiST) for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome: a Single Arm Prospective Study

NCT05366517•Institute for the Study of Urological Diseases, Greece

View on ClinicalTrials.gov

Summary

The aim of the study is to investigate the efficacy and safety of LiST retreatment for CP/CPPS patients.A total of 50 patients with CP/CPPS diagnosis who were previously treated with 6 sessions of LiST will participate in this study.The primary study parameter is the CP/CPPS-related pain complaints and it will be assessed by the NIH-CPSI

Eligibility

Age

18 - 60 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•1. Participant must be between 18-60 years of age.
•2. Participant has signed and dated the appropriate Informed Consent document.
•3. Participant has had a clinical diagnosis of CP/CPPS defined as symptoms of discomfort or pain in the perineal or pelvic region for at least a three (3) month period within the last six (6) months.
•4. Participant has received 6 sessions (1/week or 2/week, energy level 7, Dornier ARIES 2) of LIST the last 12 months for the treatment of CP/CPPS reporting amelioration but without complete remission of CP/CPPS symptoms ( at over 1 UPOINT positive domain).

Exclusion Criteria

•1. Participant has evidence of facultative Gram negative or enterococcus with a value of ≥ 1000 CFU/ml in mid-stream urine (VB2).
•2. Participant has a history of prostate, bladder or urethral cancer.
•3. Participant has undergone pelvic radiation or systemic chemotherapy.
•4. Participant has undergone intravesical chemotherapy.
•5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition associated with LUTS, any neurological disease or disorder affecting the bladder.
•6. Participant has undergone prostate surgery or treatment.
•7. Participant with penile or urinary sphincter implants.
•8. Participant has been diagnosed with cancer during the last 5 years, or had any surgery in the pelvis.
•9. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.

Key Dates

Start Date

September 1, 2022

Primary Completion Date

September 1, 2023

Completion Date

December 1, 2023

Last Updated

May 9, 2022

Enrollment

ESTIMATED participants

Conditions

Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Interventions

Dornier Aries 2 device

DEVICE

Contacts

Paraskevi kapoteli

CONTACT

2310963102 pkapotel@auth.gr

Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT04275297

Chronic Interstitial CystitisBladder Pain Syndrome+9 more

View study

COMPLETEDPHASE2

Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

NCT04552431

Chronic Prostatitis With Chronic Pelvic Pain Syndrome

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome

Inclusion Criteria

Exclusion Criteria

Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome